Accessibility Menu

Freenome(NASDAQ) FRNM

Market Cap$115.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+11%
5 YearN/A
1 Year+5%
1 Month-2%
$11.11
+1.83%
+0.20Today
After hours$11.06-$0.05 (-0.45%)
Freenome last closing stock price
MetricPriceDate
Last closeUSD 11.152026-08-07
Freenome stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 11.152026-07-31
1 month-2.19%USD 11.402026-07-08
3 month-1.15%USD 11.282026-05-08
Year to date-14.43%USD 13.032025-12-31
1 year+5.49%USD 10.572025-08-06
Since inception+10.95%USD 10.052024-06-12

Freenome Financials at a Glance

Market Cap

$115.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$0.76

EPS (TTM)

-$0.07

P/E Ratio

-159.97

Dividend

$0.00

Beta (Volatility)

0.15 (Low)

Price

$11.11

Volume

548,629.457

Open

$10.90

Previous Close

$11.15

Daily Range

$10.90 - $11.29

52-Week Range

$9.95 - $14.47

Estimated Earnings Date

N/A

FRNM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Freenome

Freenome, Inc. is a biotechnology company focused on developing a multiomics platform for early cancer detection. The company aims to revolutionize cancer diagnostics through its innovative blood tests that analyze various biological markers.

Products and Services
  • Multiomics platform for comprehensive cancer detection
  • Blood tests that analyze DNA, RNA, and proteins
  • Partnerships with healthcare providers for clinical applications
Growth Outlook
  • Market demand for early cancer detection is increasing
  • Potential for expansion into new diagnostic areas
  • Strategic partnerships may enhance market reach
Financial Highlights
  • Market capitalization of approximately $91.7 million
  • Stock price range between $9.95 and $14.47 over the year
  • Average trading volume of 168,291 shares
Freenome, Inc. operates in a rapidly evolving sector with significant potential for growth. The increasing focus on early cancer detection aligns with the company's innovative approach, making it a noteworthy player in the biotechnology field. The strategic partnerships and market demand for its products may further enhance its position in the industry. The financial metrics indicate a stable market presence, with a solid market capitalization and consistent trading activity.
AI Generated • Jul 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Aaron Elliott, PhD

Website

www.perceptivelife.com/pcsc

Headquarters

Brisbane, CA 94005, US

FRNM Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-91.65%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-0.63%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$115.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.31M

Volume

548.63K

Avg. Volume

293.09K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Freenome Performance Analysis

Freenome annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Freenome annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD 0.17N/A
20252025-12-31USD 0.08-56.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

N/A

N/A

Market Cap

$115.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$37.40

N/A

Employees

3

N/A

Net Income

-$0.11

-0.2%

EBITDA

-$0.94

+4.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$0.44

-67.5%

Total Debt

$0.00

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-86.06%

-0.2%

Return on Invested Capital

1.59%

+0.7%

Free Cash Flow

-$0.13

+0.9%

Operating Cash Flow

-$0.13

+0.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,757.64+0.01%
^DJIDJI
$54,036.93+0.00%
^IXICNASDAQ
$26,690.62+0.01%
BTCBitcoin
$64,991.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About FRNM

What is the current price of Freenome?

Freenome is trading at $11.15 per share.

What is the 52-week range for Freenome?

Over the past 52 weeks, Freenome has traded between $9.95 and $14.47.

How much debt does Freenome have?

As of the most recent reporting period, Freenome reported total debt of $0.00.

How much cash does Freenome have on hand?

Freenome reported $437.37K in cash and cash equivalents in its most recent financial results.

What is Freenome’s dividend yield?

Freenome does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services